drugset

drugset / Trial / NCT02053974

Spironolactone Against Anthracycline-induced Cardiomyopathy

NCT02053974 ↗

Phase 4 Completed 90 enrolled TC Erciyes University

RandomizedParallel-groupTriple-blindPrevention

Summary

This study sought to investigate the whether spironolactone protects the heart against anthracycline-induced cardiotoxicity.

Timeline

Start: 2011-09
Primary completion: 2012-10
Completion: 2012-10

Publications

Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, Berk V, Karaca H, Kalay N, Oguzhan A, Ergin A. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 2015 Jan;17(1):81-9. doi: 10.1002/ejhf.196. Epub 2014 Nov 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Spironolactone	Small molecule	25 mg	Oral

Indications